Randomized single-blind trial protocol reports planned evaluation of Moshen Digui for proteinuria in idiopathic membranous nephropathy, highlighting novel therapeutic options.
Background: Idiopathic membranous nephropathy (IMN) has been the most common cause of primary nephrotic syndrome in adults. Moshen Digui (MSDG) prescription has been widely used in the treatment of IMN. Our Trial aims to evaluate effectiveness and security of MSDG prescription in the treatment of IMN. Methods: our trial is a 12-week, randomized, controlled, and single-blind trial. Patients of IMN were randomly divided into control group (n=30) and therapeutic group (n=30). Therapeutic group was given to MSDG prescription. Control group was given to placebo. Urinary protein of 24 h, as the key outcome of our Trial, was detected at 0, 4, 8, 12 weeks. Safety will be assessed throughout. Discussion: our study will provide the initial evidence about the efficacy and safety of MSDG prescription in treatment of IMN. Trial registration: ChiCTR1800015866.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: